Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.In an interview with Healio, ...

What's better than a good thing? More of a good thing. Income investors can find plenty of "good things" in the market these ...

The doctor beamed onto a health clinic video screen in October to convince the regional health board to ban public clinics in ...

We recently published a list of Why Are These 10 Dividend Stocks Declining? In this article, we are going to take a look at ...

There are some new tools to help this respiratory virus season: over-the-counter tests that can identify whether an illness ...

Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

We in Chautauqua County know all about grapes and wine, and for more than 150 years we supplied the world. But now we have a new product from individuals in CHQ who have perfected the art of Making ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

Since 1999, Feb. 7 has marked National Black HIV/AIDS Awareness Day, drawing attention to the disproportionate impact of HIV ...